Jove
Visualize
Contact Us

Related Experiment Videos

New central dopamine agonists.

J Borsy

    Polish Journal of Pharmacology and Pharmacy
    |May 1, 1985
    PubMed
    Summary

    A novel ergot derivative, GYKI-32 887, shows potent dopamine receptor agonist activity. This compound demonstrates superior efficacy in inhibiting prolactin secretion and treating parkinsonism compared to bromocriptine.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preclinical studies with compound GYKI-22441, a new long-acting neuroleptic phenothiazine.

    Acta physiologica Hungarica·1990
    Same author

    Anti-amnesic effect of a thiazolidine compound, GYKI-20 238.

    Acta physiologica Hungarica·1990
    Same author

    Effect of amprilose on various immunological and inflammatory animal models.

    Acta physiologica Hungarica·1990
    Same author

    Neuropharmacology of a new psychotropic 2,3-benzodiazepine.

    Arzneimittel-Forschung·1987
    Same author

    The effect of GYKI-32 887 on dopamine (D2) and serotonin (5-HT1 and 5-HT2) receptors.

    Polish journal of pharmacology and pharmacy·1985
    Same author

    The role of central dopamine (DA) receptors in the regulation of blood pressure.

    Polish journal of pharmacology and pharmacy·1985
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Endocrinology

    Background:

    • Dopamine receptor agonists are crucial for treating parkinsonism, endocrine, and cardiovascular diseases.
    • Ergot derivatives like bromocriptine are established therapies.
    • Research focuses on developing novel dopamine agonists with improved efficacy.

    Purpose of the Study:

    • To evaluate the endocrinological effects and dopamine receptor stimulant activity of novel elymoclavine derivatives.
    • To identify the most potent dopamine agonist for preclinical investigation.
    • To compare the efficacy of GYKI-32 887 with existing treatments like bromocriptine.

    Main Methods:

    • Synthesis of semi-synthetic elymoclavine derivatives.
    • Examination of central and peripheral dopamine transmission.
    • Assessment of prolactin secretion inhibition and antiparkinsonian efficacy.
    • Evaluation of bicuculline-induced convulsion inhibition.

    Main Results:

    • Compound GYKI-32 887 emerged as the most effective dopamine agonist among synthesized derivatives.
    • GYKI-32 887 demonstrated greater potency than bromocriptine in inhibiting prolactin secretion.
    • GYKI-32 887 exhibited superior antiparkinsonian efficacy compared to bromocriptine.
    • Unlike bromocriptine, GYKI-32 887 inhibited bicuculline-induced convulsions, suggesting GABA receptor agonistic effects.

    Conclusions:

    • GYKI-32 887 is a highly potent dopamine receptor agonist with significant therapeutic potential.
    • Its superior efficacy over bromocriptine in prolactin inhibition and antiparkinsonian effects warrants further investigation.
    • The observed GABA receptor agonistic activity suggests potential applications in treating dyskinesias.

    Related Experiment Videos